Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Amgen

Related AMGN
Lightning Round: Jim Cramer Gives His Opinion On Delta, Sangamo, Kinder Morgan And More
Amgen, Goldman Sachs, Micron, Paypal: Fast Money Picks For October 18
Financial Advisory Service, Inc. Buys iShares MSCI EAFE Value, S&P 5…… Insurance, ... (GuruFocus)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Amgen (NASDAQ: AMGN), and raised its price target from $92.00 to $100.00.

Jefferies noted, “AMGN reported ~in-line 3Q12 total product sales and ~10% beat on EPS on lower OpEx; upped FY12 guidance for revenue slightly and EPS by ~4-5% to partly reflect 3Q12 EPS beat. At its reasonable valuation (~12.6x '13 earnings vs. ~15x for peers vs. ~12x for pharma), stable current revenue, some promising products in development, and increasing quarterly cash dividend ($0.36 in 4Q12 from $0.28 in 3Q11), AMGN represents a good value play.”

Amgen closed on Tuesday at $87.32.

Latest Ratings for AMGN

Oct 2017BarclaysMaintainsEqual-Weight
Oct 2017Morgan StanleyMaintainsOverweight
Sep 2017Credit SuisseMaintainsOutperform

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (AMGN)

View Comments and Join the Discussion!

Partner Center